McKesson Corporation with ticker code (MCK) now have 16 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 222 and 178 with a mean TP of 197.5. Now with the previous closing price of 179.75 this indicates there is a potential upside of 9.9%. The day 50 moving average is 162.71 and the 200 day moving average is 154.29. The market cap for the company is $28,821m. Visit the company website at: http://www.mckesson.com
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and solutions for life sciences companies, including offering multiple distribution channels and clinical trial access to specific patient populations through its network of oncology physicians. The segment also sells financial, operational and clinical solutions to pharmacies; and offers consulting, outsourcing, and other services. The Prescription Technology Solutions segment operates in the healthcare delivery system to connect pharmacies, providers, payers, and biopharma for next-generation patient access and adherence solutions. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.